FDA Approval in Metastatic Uveal Melanoma
Jan 28, 2022•12 min•Ep. 129
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
On this episode, we'll be talking about an FDA approval for uveal melanoma, as well as the efficacy of PD-1 inhibition in patients with resectable liver cancer.
Coverage of stories discussed this week on ascopost.com:
FDA Approves Tebentafusp-tebn for the Treatment of Unresectable or Metastatic Uveal Melanoma
Neoadjuvant Cemiplimab-rwlc for Patients With Resectable Hepatocellular Carcinoma
To listen to more podcasts from ASCO, visit asco.org/podcasts.
For the best experience, listen in Metacast app for iOS or Android